The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
Open accessAbstract
Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial–mesenchymal transition (EMT) and sorafenib resistance remain enigmatic. In the present study, forced Gal-1 expression promoted HCC progression and sorafenib resistance. Gal-1 elevated α v β 3-integrin expression, leading to AKT activation. Moreover, Gal-1 overexpression induced HCC cell EMT via PI3K/AKT cascade activation. Clinically, our data revealed that Gal-1 overexpression is correlated with poor HCC survival outcomes and sorafenib response. These data suggest that Gal-1 may be a potential therapeutic target for HCC and a biomarker for predicting response to sorafenib treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Cited by
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Zhang, B., Zhang, Y., Zhang, J., Liu, P., Jiao, B., Wang, Z., & Ren, R. (2021) · Advanced Science · doi:10.1002/advs.202100250 · Cited by 83
Pan, G., Huang, M., Fu, S., Wang, Y., He, L., Wu, B., Yang, J., Lin, S., & Fan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-06294-1 · Cited by 3
Metadata
- Authors
- Zhang, P.-F., Li, K.-S., Shen, Y.-H., Gao, P.-T., Dong, Z.-R., Cai, J.-B., Zhang, C., Huang, X.-Y., Tian, M.-X., Hu, Z.-Q., Gao, D.-M., Fan, J., Ke, A.-W., & Shi, G.-M.
- Venue
- Cell Death & Disease
- Published
- 2016-04-21
- Volume
- 7
- Issue
- 4
- Pages
- e2201-e2201
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2340909115
- Cited by
- 247
- References
- 2
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. https://app.cochat.ai/papers/10.1038/cddis.2015.324
- The paper
- Zhang, P.-F., Li, K.-S., Shen, Y.-H., Gao, P.-T., Dong, Z.-R., Cai, J.-B., Zhang, C., Huang, X.-Y., Tian, M.-X., Hu, Z.-Q., Gao, D.-M., Fan, J., Ke, A.-W., & Shi, G.-M. (2016). Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death & Disease. https://doi.org/10.1038/cddis.2015.324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.